has divulged incretin analogues acting as dual agonists of gastric inhibitory polypeptide (GIPR) receptor/GLP-1 or GLP-1/glucagon receptor (GCGR) or triple agonists of GIPR/GLP-1/GCGR reported to be useful for the treatment of type 2 diabetes, dyslipidemia, obesity, metabolic syndrome, neurodegeneration, fibrosis and cardiovascular disorders
In clinical studies[7], the most common reactions included: Flushing Injection site reactions Headache Vomiting Blurred vision Joint pain or swelling Nasal congestion Cough Darkening of the skin on the face, gums, or breasts These effects can be uncomfortable, but theyre typically short-lived and manageable for most people
Symptoms to watch for include prolonged redness, swelling, itching, or bumps at the injection site
Post-Treatment Follow-Up At evaluation 3 months postradiation, the patients skin showed no residual reaction other than mild hyperpigmentation
The impact of drug coverage isnt limited to price points and direct patient outcomes: a survey from 9amHealth revealed that 67% of Americans would prefer to stay at a job they don't like as opposed to starting a new job, just to keep insurance coverage for weight loss medications